anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses plaster for curing bone diseases, which comprises the following components by weight portions: 1 to 3 portions of borneol, 3 to 10 portions of rhubarb, 8 to 15 portions of phellodendron bark, 5 to 10 portions of myrrh, 5 to 10 portions of frankincense, 5 to 15 portions of dragon blood and 20 to 60 portions of gardenia. The gardenia in the plaster of the present invention can remove heat from the blood and remove toxic substances, and the frankincense can promote blood circulation, alleviate pain and relax tendons. The rhubarb can remove heat from the blood and reomve toxic substances and can dispell clots to dredge collateral. The phellodendron bark can clear heat, dry dampness and remove toxic substances. The myrrh can remove blood stasis, alleviate pain and remove tumefaction and pain. The dragon blood can alleviate pain, strengthen muscle and break hematocele and blood accumulation of internal damage. The borneol can clear away heat, alleviate pain and induce resuscitation. When all of the medicine is combined together, the present invention can remove rheumatism, dispell cold and cool, remove tumefaction, alleviate pian and clear away blood stasis. Therefore, the blood circulation is smooth, and personal disease resisting capability is improved. Meanwhile, the present invention can repair bone tissue and generate periosteum. The curative time of the present invention is short, and a recurrence rate after healing is low. Moreover, the present invention also has conspicuous curative effects on female hyperplasia of mammary glands.
Bracing with a rigid TLSO is gold-standard treatment in terms of halting progression of idiopathic scoliosis in skeletally immature adolescents and children. The treatment is cumbersome and demanding for adolescents during a vulnerable stage in life, and may be associated with poor compliance. Furthermore, the treatment lasts in many cases for several years and has shown to have a negative psychological effect for patients. Since time in brace is of utmost importance for best possible outcome, the braces need to be tolerated by the patients. As of today, 3D designed braces have received much attention and are thought to increase comfortability and ultimately increase wearing time, leading to better outcomes.

In a multicenter randomized controlled trial, we seek to compare standard Boston brace to a newly developed 3D designed Boston brace. Skeletally immature patients with idiopathic scoliosis will be randomized to receive either standard Boston brace or Boston 3D brace. All patients will be encouraged to be physically active for 60 minutes per day. Patients, outcome assessors and clinician in charge during follow-ups will be blinded for the type of brace the patients are being treated with. Thermal sensors will be installed in all braces to monitor compliance. Outcome include change in curve severity, quality of life and surgical rates. Patients will be evaluated with clinical and radiological follow-ups every six months until skeletal maturity and thereafter at 2, 5 and 10 years. Curve progression will not lead to change of brace. A total of 85 individuals are required in each group based on the hypothesis of a 2% failure rate in the 3D-brace group and 15% in the standard brace group with 5% significance level and 80% power and consideration for dropout of up to 20%.

For individuals who are not willing to be randomized and participate in the study, standard Boston brace will be offered and these individuals will serve as an observational group with similar follow-ups and will be asked to answer same survey as the study populations will do.
Healthcare professionals should pay special attention to accurate calculation of the dose of RETROVIR, transcription of the medication order, dispensing information, and dosing instructions to minimize risk for medication dosing errors.

Prescribers should calculate the appropriate dose of RETROVIR for each child based on body weight (kg) and should not exceed the recommended adult dose.

Before prescribing RETROVIR capsules, children should be assessed for the ability to swallow capsules. If a child is unable to reliably swallow a RETROVIR capsule, the RETROVIR oral solution formulation should be prescribed.

The recommended oral dosage in pediatric patients aged 4 weeks to less than 18 years and weighing greater than or equal to 4 kg is provided in Table 1. RETROVIR oral solution should be used to provide accurate dosage when capsules are not appropriate.

Alternatively, dosing for RETROVIR can be based on body surface area (BSA) for each child. The recommended oral dose of RETROVIR is 480 mg per m2 per day in divided doses (240 mg per m2 twice daily or 160 mg per m2 three times daily). In some cases the dose calculated by mg per kg will not be the same as that calculated by BSA.
<P>PROBLEM TO BE SOLVED: To provide a retro-inverso peptide which is derived from interleukin-3 (IL-3), comprises a specific sequence, has activities similar to that of the native parent protein, and also has neurotrophic activity.  <P>SOLUTION: In one aspect of this preferred embodiment, at least one basic charged amino acid of the sequence is replaced with a different basic charged amino acid. In another aspect of this preferred embodiment, at least one acidic charged amino acid of the sequence is replaced with a different acidic charged amino acid. Advantageously, at least one non-polar amino acid of the sequence is replaced with a different non-polar amino acid. Preferably, at least one non-charged amino acid of the sequence is replaced with a different non-charged amino acid. In another aspect of this preferred embodiment, at least one aromatic amino acid of the sequence is replaced with a different aromatic amino acid.  <P>COPYRIGHT: (C)2011,JPO&INPIT
SLE in paediatric patients requires long-term treatment with several side effects. Nigella sativa is known to have immunomodulatory effects. Our study aimed to investigate the immune-modulatory effects of Nigella sativa oil on T lymphocyte activity, inflammatory cytokine profile, and improvement of SLEDAI score in our patients. This was a placebo-controlled clinical trial of Nigella sativa oil administration in 32 paediatric SLE patients who were tested before and after treatment. The study subjects were randomly assigned. Patients had blood samples taken to be tested for T cell ratio, percentage of a number of cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-17, and IL-10) using flow cytometry and CBA (Cytometric Bead Array), and SLEDAI score at the beginning of the study and after treatment. They were treated with 1 gram of N. sativa oil capsules and 1 gram of placebo daily for 8 weeks.
Total dose delivered and tumor size are important predictors of local control in the treatment of low-grade Non-Hodgkin's Lymphoma (NHL). The basic principle is that larger nodal masses require increased doses of External Beam Radiotherapy (EBRT) to achieve local control. Radioimmunotherapy (RIT) seems to share this same characteristic. Review of the published literature on both Bexxar and Zevalin reveals that one of the most important predictors of treatment failure is nodal volume and its apparent relationship to dose delivered by RIT. The best tumor dosimetry for RIT is from Dr. Wiseman et al reporting on the dosimetry of Zevalin (PMID:11418315). He showed that tumors ≥15 cm\^3 received only 1082 cGy with Zevalin, whereas the average dose delivered in tumors \<15 cm\^3 was 4763 cGy. Recently, Gokhale et al (PMID:16111589) published their experience with Zevalin at Cleveland Clinic and showed a significant correlation with pretreatment tumor volume and response to therapy. In their experience, tumors ≥5 cm had an 83% rate of local recurrence versus 28% for tumors \<5 cm. This dosing paradox (bigger masses, which require more dose, receive less with RIT) may be diminished by the delivery of additional EBRT. This is the hypothesis that underlies the pilot study.

The dosimetric data available for Bexxar is more heterogeneous but confirms the observations seen with Zevalin. In patients previously untreated for low-grade Non-Hodgkin's Lymphoma (NHL), Koral et al (PMID:12621015) showed an increased likelihood of achieving a complete response (CR) if tumor doses were \>650 cGy. Previous work by these same authors showed a trend for larger tumor volumes receiving less dose (PMID:10994741). The most compelling data for this relationship comes from the clinical trials done using Bexxar. Both in the pivotal trial (PMID:11579112) and the recently published trial treating naïve patients (PMID:15689582), tumor volume was a significant predictor of response to Bexxar. In the pivotal trial, smaller tumor burden was the only factor predicting longer duration of response.

Whereas EBRT might be able to provide reliable radiation dose, the use of Bexxar may provide the therapeutic equivalent of central lymphatic irradiation, which would permit the use of true involved field radiotherapy. Investigators have previously noted that increased EBRT field size is associated with increased short-term and long-term toxicity. The toxicities associated with the treatment of radiotherapy are related to the site treated, but do not necessarily include the dose limiting toxicity of Bexxar, which is primarily hematologic and transient. As the toxicity of RT and Bexxar may not overlap, the combination of both may allow an increase in the therapeutic window for both radiotherapy and Bexxar therapy.
Kidney injury disrupts the intricate renal architecture and triggers limited regeneration, together with injury-invoked inflammation and fibrosis. Deciphering the molecular pathways and cellular interactions driving these processes is challenging due to the complex tissue structure. Here, we apply single cell spatial transcriptomics to examine ischemia-reperfusion injury in the mouse kidney. Spatial transcriptomics reveals injury-specific and spatially-dependent gene expression patterns in distinct cellular microenvironments within the kidney and predicts Clcf1-Crfl1 in a molecular interplay between persistently injured proximal tubule cells and their neighboring fibroblasts. Immune cell types play a critical role in organ repair. Spatial analysis identifies cellular microenvironments resembling early tertiary lymphoid structures and associated molecular pathways. Collectively, this study supports a focus on molecular interactions in cellular microenvironments to enhance understanding of injury, repair and disease.
FIELD: biotechnology, blood proteins. SUBSTANCE: erythrocyte hemolyzate is prepared by dilution of erythrocyte mass with distilled water at ratio = (1: 2)-(1: 4), freezing and the following concentration of hemolyzate by ultrafiltration and sterilizing filtration and lyophilization. Yield of crystalline hemoglobin is above 95%, purity is above 80%. Product is used in agriculture as food addition for treatment and prophylaxis of iron-deficiency states in animals and in human also. Product is used in diagnostic investigations and in science studies also. EFFECT: simplified method, decreased cost, increased yield, enhanced purity of product. 1 tbl
Arm 1 participants will undergo resection/biopsy of their tumor and placement of a Rickham catheter at the site of the resection/biopsy. Patients receive chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes NCI SYs via single delivery starting on day 0 for 3 weekly cycles over 28 days. Each treatment cycle begins with one CAR T cell infusion delivered intracranial intratumoral or intracavitary \[ICT\] and lasts for 1 week. Beginning 1 week after cycle 3, patients may continue with CAR T cell treatment per principal investigator and patient discretion. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients receive cetuximab IV over 120 minutes on day -14 prior to cycle 1 and then on days 1, 15 and 29 of each cycle and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT or MRI throughout the trial and optionally undergo blood sample collection on study and at disease progression or end of treatment.
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors. In a particular embodiment the antigen receptor comprises two peptides each comprising a first domain, a second domain, a variable region of a T cell receptor chain, and an immunoreceptor signal transmission domain. The first domain from the first peptide chain interacts with one of the first and second domains from the second peptide chain to form a first antigen binding site. The second domain from the first peptide chain interacts with the other of the first and second domains of the second peptide chain to form a second antigen binding site. In addition, the first peptide chain comprises a variable region of a T cell receptor alpha chain and a constant region of a T cell receptor alpha chain and the second peptide chain comprises a variable region of a T cell receptor beta chain and a constant region of a T cell receptor beta chain. Alternatively, the first peptide chain comprises a variable region of a T cell receptor beta chain and a constant region of a T cell receptor beta chain and the second peptide chain comprises a variable region of a T cell receptor alpha chain and a constant region of a T cell receptor alpha chain.
Each capsule contains 625 mg of fish oil (100 mg EPA \& 250 mg DHA). Participants will take 12 capsules per day over 6 months.
Anal cancer is an uncommon cancer, accounting for 2% of gastrointestinal cancers. Prognostic factors include tumor differentiation and staging, along with patient gender, race, and socioeconomic status. The standard of care is radical chemoradiation with 5-fluorouracil and mitomycin C, with surgery reserved for salvage. Intensity modulated radiation therapy (IMRT) is a specialized radiotherapy technique that may be used for anal cancer. IMRT allows the radiation dose to conform to the three-dimensional shape of the target volume more than conventional two-dimensional techniques, and it may reduce treatment toxicities without compromising tumor control. At the Princess Margaret Hospital (PMH) since July 2007, IMRT for all treatment phases of radiotherapy has been implemented as standard treatment for patients with anal canal and perianal cancer.
Patients receive venetoclax PO QD on days 1-42 of cycle 1 and days 43-70 of cycle 2. Patients also receive vincristine liposomal IV over 1 hour weekly for 4 weeks starting on day 15 of cycle 1. Patients who achieve at least a stable disease response may continue treating at the discretion of the treating physician in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the trial. Patients may also undergo CT and/or PET scan as well as a lumbar puncture as clinically indicated.
BACKGROUND: Prostate cancer (PCa) is the most common non-cutaneous malignancy in men and leads to the second most common cause of cancer related mortality in men. Early detection of PCa allows for a potentially curative intervention. Most men will live over a decade from the time of their PCa diagnosis. Thus, treatments must balance curative interventions with their impact on quality of life. Radical prostatectomy (RP) is one such potentially curative intervention but often leads to erectile dysfunction (ED) and urinary incontinence (UI). Approximately 90,000 RPs are performed each year in the USA. Post-operative ED and UI is thought to occur in part from traumatic peripheral nerve injury (TPNI) to the neurovascular bundles that surround the prostate. Thus, patients undergoing RP may be a population that would benefit from clinical studies that look at TPNI.
METHODS: The study is a single-institution, double-blinded placebo-controlled, randomized clinical trial in which patients immediately post-RP receive either 4-aminopyrdine (4AP) or placebo in a 1:1 fashion. The primary outcome is evaluation of the efficacy of 4AP in accelerating the early return of baseline erectile and urinary function post-radical prostatectomy.
DISCUSSION: This study is critical as it could reduce the morbidity associated with RP, a commonly performed operation, and identify a patient population that may greatly benefit into further TPNI research.
TRIAL REGISTRATION: ClinicalTrials.gov NCT03701581. Prospectively registered on October 10, 2018.
Our inclusion criteria for the nurses are the following: (1) 18 years old or older; (2) currently employed as a licensed nurse; and (3) current employment duties include routinely assessing the musculoskeletal pain of cognitively intact, adult outpatients. Our exclusion criteria for the nurses are the following: (1) currently managing a painful musculoskeletal condition; and (2) has ever felt musculoskeletal pain on most days for 3 months or longer.
The invention discloses a sugar-polyethylene glycol-DSPE coupling compound and a preparation method and application thereof. Wherein the sugar-polyethylene glycol-DSPE coupling compound is obtained by coupling sugar with phosphatidylethanolamine (DSPE) -polyethylene glycol (PEG). The sugar is monosaccharide, disaccharide, polysaccharide or acetylated sugar, wherein the monosaccharide comprises mannose, galactose, arabinose and glucose, the disaccharide comprises maltose disaccharide, and the polysaccharide comprises maltotriose. DPSE is an artificially synthesized phospholipid with lipophilic action, PEG is a hydrophilic substance, and a sugar ligand is a target of a targeting material. The compound of the invention can be used for designing targeting vectors, particularly liposomes and micelles, and can also be used as a surfactant. In addition, the invention also provides a preparation method of the compound, and the preparation method has the advantages of easily obtained raw materials, mild reaction conditions, easy control, simple operation, easy purification of the product and high yield. The product can be applied to biological research and has important significance for preparing drug carriers and treating diseases.
Immobilisation discontinued on the basis of MRI defined disease resolution at 3, 6, 9 or 12 months. In the intervention arm participants will receive additional MRIs at 3, 6, 9 and 12 months. Patients randomised to serial MRI will not undergo further MRI once remission has been diagnosed i.e. if remission is diagnosed at 6 months the MRI at 9 and 12 months will not occur.
The present invention relates to a composition for treating intractable ankylosing spondylitis accompanied by metabolic abnormalities. The present invention confirmed that the diversity of intestinal flora was reduced in patients with ankylosing spondylitis and patients with ankylosing spondylitis accompanied by metabolic abnormalities, and that the composition ratio of intestinal flora was different from the composition ratio of normal people. In addition, it was confirmed that when patient-derived PBMCs were treated with Faecalibacterium prausnitzii, which is the microbiome of the genus Faecalibacterium which was found to be reduced in a patient group, Tregs and Th17 cells were regulated. In addition, it was confirmed that treatment with sodium butyrate in an ankylosing spondylitis animal model with metabolic abnormalities reduced the index and induction rate of arthritis due to ankylosing spondylitis and inhibited damage to joints and spinal tissues. In addition, it was confirmed that the composition effectively regulates immune cells Th17, Th1, Th2, and Tregs, and regulates differentiation of Th17 and Tregs. In addition, it was confirmed that bone damage can be improved by suppressing osteoclast differentiation, and it was confirmed to be effective in ankylosing spondylitis accompanied by metabolic abnormalities.
Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
Female Pattern Hair Loss (FPHL) is a common form of non-scaring hair loss that occurs in adult women. Although several treatments have already been proposed for FPHL, only Topical Minoxidil accumulated an adequate level of evidence. This study aimed to evaluate the therapeutic response of MMP® (intradermal infiltration) of Minoxidil formulation in the frontal-parietal-vertex regions compared with the gold-standard home administration of Minoxidil 5% Capillary Solution. This self-controlled comparative study evaluated 16 FPHL patients, without treatment for at least 6 months, confirmed by trichoscopy with TrichoLAB® software. They received 4 monthly sessions of MMP® with Minoxidil 0,5% on the right side of the scalp (frontal-parietal-vertex areas), followed by occlusion with plastic film for 12 h and prescription of Minoxidil 5% Solution for home use once a day, on both scalp sides, starting 72 h after the procedure. The reassessment trichoscopy was 6 weeks after the last session and they answered a "self-assessment" questionnaire. Treated scalp areas were compared and showed both treatments, in general, were effective, with no difference between them. If they were analyzed separately by treated areas, there were signs of better response in the parietal-vertex regions with treatment by MMP® with Minoxidil, while clinical treatment indicated a better response in the other regions. When patients were divided into more and less advanced cases, a better response in parietal-vertex regions treated by MMP® with Minoxidil in less advanced patients was confirmed. MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced FPHL patients. It represents yet another resource to improve quality of life of these suffering patients.
This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.